欧康维视生物-B(01477)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01477 欧康维视生物-B

未开盘 12-10 16:08:20

8.260

-0.140

-1.67%

最高8.520	最低8.150	成交量75.20万
今开8.200	昨收8.400	日振幅4.40%
总市值67.32亿	流通市值67.32亿	总股本8.15亿
成交额629.03万	换手率0.09%	流通股本8.15亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01477","market":"HK","secType":"STK","nameCN":"欧康维视生物-B","latestPrice":8.26,"timestamp":1765354100003,"preClose":8.4,"halted":0,"volume":752000,"delay":0,"floatShares":815000000,"shares":815000000,"eps":-0.43193492611266737,"marketStatus":"未开盘","change":-0.14,"latestTime":"12-10 16:08:20","open":8.2,"high":8.52,"low":8.15,"amount":6290305,"amplitude":0.044048,"askPrice":8.26,"askSize":4000,"bidPrice":8.23,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-0.36645173993152824,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765416600000},"marketStatusCode":0,"adr":0,"listingDate":1594310400000,"exchange":"SEHK","adjPreClose":8.4,"openAndCloseTimeList":[[1765330200000,1765339200000],[1765342800000,1765353600000]],"volumeRatio":1.395694,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01477/wiki","defaultTab":"wiki","newsList":[{"id":"2590158116","title":"重药控股最新公告：参股子公司药友制药与辉瑞签订许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2590158116","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590158116?lang=zh_cn&edition=full","pubTime":"2025-12-10 19:50","pubTimestamp":1765367412,"startTime":"0","endTime":"0","summary":"重药控股(000950.SZ)公告称，公司参股子公司药友制药与辉瑞签订许可协议，药友制药授予辉瑞在全球范围内及人类、动物所有适应症的治疗、诊断及预防领域独家开发、使用、生产及商业化口服小分子胰高血糖素样肽-1受体（GLP-1R）激动剂（包括YP05002）及含有该活性成分的产品。就本次许可，药友制药将有权依约获得（其中包括）不可退还的首付款 15,000万美元及基于许可产品临床、商业化进展获得开发里程碑付款至多35,000万美元。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121000035059.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK1191","BK0071","BK0250","000950","01477"],"gpt_icon":0},{"id":"2590300641","title":"歌礼制药-B(01672)：同类首创FASN抑制剂地尼法司他(ASC40)治疗痤疮的新药上市申请获国家药监局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2590300641","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590300641?lang=zh_cn&edition=full","pubTime":"2025-12-10 17:06","pubTimestamp":1765357565,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B 发布公告，董事会宣布同类首创、每日一次口服小分子脂肪酸合成酶抑制剂地尼法司他治疗中重度寻常性痤疮的新药上市申请获中国国家药监局受理。地尼法司他显示出了良好的安全性与耐受性特征。未有观察到与地尼法司他 相关的永久性终止治疗或煺出试验的情况。公司已于近期完成与中国国家药监局就地尼法司他治疗中重度寻常性痤疮的新药上市申请前沟通并收到国家药监局的积极反馈。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1379888.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01477","BK1515","BK1191","BK1574","01672","BK1161"],"gpt_icon":0},{"id":"1102748254","title":"港股创新药概念股盘初普跌！歌礼制药-B跌近6%、金斯瑞生物科技跌近5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1102748254","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102748254?lang=zh_cn&edition=full","pubTime":"2025-12-10 09:44","pubTimestamp":1765331074,"startTime":"0","endTime":"0","summary":"12月10日，港股创新药概念股盘初普跌，$歌礼制药-B(01672)$跌近6%，$金斯瑞生物科技(01548)$跌近5%，$再鼎医药(09688)$跌超3%，$康方生物(09926)$、$药明康德(00013)$、$药明生物(02269)$跌超2%.","market":"hk","thumbnail":"https://static.tigerbbs.com/c7da52addfd52fb216bcf87283f43750","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/c7da52addfd52fb216bcf87283f43750"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0456827905.SGD","LU0572944931.SGD","ZLAB","IE00B0JY6N72.USD","BK1141","LU1880383366.USD","HK0000306701.USD","BK4588","LU0417516571.SGD","BK1515","BK4585","LU0307460666.USD","LU1242518857.USD","BK1610","LU2039709279.SGD","LU0823426308.USD","HK0000306685.HKD","HK0000320223.HKD","LU0456846285.SGD","LU1242518931.SGD","BK1589","LU0320764599.SGD","LU2476274720.SGD","LU0181495838.USD","BK1521","LU0417516902.SGD","09926","LU0561508036.HKD","BK4548","SG9999002463.SGD","LU0516423174.USD","LU1794554557.SGD","LU0052750758.USD","LU0327786744.USD","LU0348827113.USD","LU1688375341.USD","LU0348766576.USD","BK1161","LU0140636845.USD","LU0856984785.SGD","02269","LU2488822045.USD","LU1720050803.USD","LU2778985437.USD","LU0326950275.SGD","LU0348783233.USD","BK4526","BK1576","BK4531","BK4139","LU0823426480.USD","LU0708995583.HKD","LU0516423091.SGD","BK1574","LU1961090484.USD","LU0516422366.SGD","LU0819121731.USD","LU0348784397.USD","IE00B543WZ88.USD","LU0348825331.USD","LU0516422440.USD","LU0634319403.HKD","01548","SG9999002562.SGD","LU2476274308.USD","LU0588546209.SGD","HK0000320264.USD","IE00BPRC5H50.USD","LU2399975544.HKD","01477","LU0359201612.USD","IE00B5MMRT66.SGD","LU0359202008.SGD","LU0043850808.USD","LU0348735423.USD","09688","LU0039217434.USD","06978","01672","LU0540923850.HKD","LU3063872942.SGD","LU0516422952.EUR","LU0348767384.USD","BK1588","LU0417516738.SGD","LU0979878070.USD","BK1583","LU0051755006.USD"],"gpt_icon":0},{"id":"2590310434","title":"复星医药最新公告：控股子公司药友制药与辉瑞签订许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2590310434","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590310434?lang=zh_cn&edition=full","pubTime":"2025-12-09 19:00","pubTimestamp":1765278029,"startTime":"0","endTime":"0","summary":"此外，基于许可产品的年度净销售额达成情况，由辉瑞向药友制药依约支付至多15.85亿美元的销售里程碑款项。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"6692cc092fbadfcafce950a9c4d79e01","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120900030616.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","BK0175","BK0239","BK1191","01477","600196","BK0188","BK1574","BK1593","BK0028","BK0187","BK0183","BK0196","BK0012","BK0060","BK0096","02196"],"gpt_icon":0},{"id":"2590311199","title":"美股异动丨诺华制药盘前涨近2%，布局过敏性疾病新靶点","url":"https://stock-news.laohu8.com/highlight/detail?id=2590311199","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590311199?lang=zh_cn&edition=full","pubTime":"2025-12-09 17:27","pubTimestamp":1765272424,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["IE0002141913.USD","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","IE0009355771.USD","LU0211331839.USD","IE00B2B36J28.USD","BK1574","IE00B4R5TH58.HKD","BK4007","NVS","BK4588","01477","LU0208291251.USD","BK4585","BK1191","IE00BJJMRZ35.SGD","BK4578","BK4532","LU0320765489.SGD","LU0070302665.USD"],"gpt_icon":0},{"id":"2590348238","title":"每日卖空追踪 | 欧康维视生物-B 12月09日卖空量成交6.75万股，卖空比例为10.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590348238","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590348238?lang=zh_cn&edition=full","pubTime":"2025-12-09 16:30","pubTimestamp":1765269021,"startTime":"0","endTime":"0","summary":"欧康维视生物-B北京时间12月09日，涨0.96%，卖空量成交6.75万股，较上一交易日减少15.09%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251209163321979825b6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251209163321979825b6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","01477","BK1191"],"gpt_icon":0},{"id":"2590348263","title":"欧康维视生物-B12月09日获主力加仓136.6万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2590348263","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590348263?lang=zh_cn&edition=full","pubTime":"2025-12-09 16:15","pubTimestamp":1765268156,"startTime":"0","endTime":"0","summary":"12月09日, 欧康维视生物-B股价涨0.96%，报收8.40元，成交金额543.6万元，换手率0.08%，振幅2.52%，量比1.00。欧康维视生物-B今日主力资金净流入136.6万元，上一交易日主力净流入14.4万元。该股近5个交易日上涨5.93%，主力资金累计净流入121.8万元；近20日主力资金累计净流出579.1万元，其中净流出天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251209162145a72cea21&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251209162145a72cea21&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","01477","BK1191"],"gpt_icon":0},{"id":"2590390096","title":"诺华制药(NVS.US)17亿美元押注英国AI药企 布局过敏性疾病新靶点","url":"https://stock-news.laohu8.com/highlight/detail?id=2590390096","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590390096?lang=zh_cn&edition=full","pubTime":"2025-12-09 15:03","pubTimestamp":1765263792,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，诺华制药将支付英国生物技术公司 Relation Therapeutics Ltd. 高达 17 亿美元，以帮助寻找治疗过敏性疾病的药物靶点。今年早些时候，诺华制药同意以 14 亿美元收购 Tourmaline Bio 公司，从而获得一种有望减轻全身性炎症的治疗方法。该公司还同意以最高 17 亿美元的价格收购美国生物技术公司 Regulus Therapeutics，并通过收购美国生物技术公司 Anthos Therapeutics 进一步丰富其心脏病学产品组合，以获得一种预防中风的药物。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1379249.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE0002141913.USD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","BK4585","BK4007","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","LU0320765489.SGD","LU0070302665.USD","BK4588","01477","LU0211331839.USD","BK1574","LU0208291251.USD","IE0009355771.USD","NVS","BK4532","BK4578","BK1191"],"gpt_icon":0},{"id":"2590563397","title":"花旗：歌礼制药-BASC30 IIa期数据进一步展现同类最佳潜力 重申“买入/高风险”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2590563397","media":"新浪港股","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590563397?lang=zh_cn&edition=full","pubTime":"2025-12-09 14:17","pubTimestamp":1765261020,"startTime":"0","endTime":"0","summary":"　　花旗发布研报称，预期歌礼制药-B股价将有正面反应； 重申“买入/高风险”评级，目标价32港元。花旗认为歌礼制药公布其口服GLP-1药物ASC30用于治疗肥胖症的美国IIa期研究正向数据进一步展现了ASC30同类最佳的潜力，并增强了未来合作信心。　　ASC30的20毫克、40毫克及60毫克剂量组因不良事件中止治疗的比例仅为7.3%、7.5%及0%，为同类药物中最佳。公司计划于2026年第一季度向美国FDA提交数据并申请II期结束会议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":"95d366eecc89ac0bd38c9eeb3f7e1a69","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkgg/2025-12-09/doc-inhaeqei1565291.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["01477","01672"],"gpt_icon":0},{"id":"2590395753","title":"港股窄幅震荡，利好刺激 歌礼制药涨超23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590395753","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590395753?lang=zh_cn&edition=full","pubTime":"2025-12-09 10:50","pubTimestamp":1765248600,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！　　港股速报 | 港股窄幅震荡 利好刺激 歌礼制药涨超23%. 　　12月9日早盘，港股市场小幅高开后窄幅震荡。　　截至发稿，恒生指数报25747.45点，下跌17.31点，跌幅0.07%。　　恒生科技指数报5640.40点，下跌22.15点，跌幅0.39%。　　焦点公司方面，歌礼制药高开高走，截至发稿涨超23%。投资者据此操作，风险自担。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2025-12-09/doc-inhaeiwp1044224.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-12-09/doc-inhaeiwp1044224.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1191","BK1161","01672","BK1574","01477","BK1515"],"gpt_icon":0},{"id":"1166068199","title":"港股生物医药股表现活跃！歌礼制药-B涨超20%，圣诺医药-B涨超13%","url":"https://stock-news.laohu8.com/highlight/detail?id=1166068199","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166068199?lang=zh_cn&edition=full","pubTime":"2025-12-09 10:02","pubTimestamp":1765245754,"startTime":"0","endTime":"0","summary":"12月9日，港股$生物(000504)$医药股表现活跃，$歌礼制药-B(01672)$涨超20%，$圣诺医药-B(02257)$涨超13%，$昭衍新药(06127)$涨超10%，$药明合联(02268)$涨超4%，$药明生物(02269)$、$药明康德(02359)$涨超3%。","market":"hk","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"eb673bcce88aebafcbc37fb491eb2df2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672","161726","BK1161","01477","02257","BK1515","BK1191","399441","BK1574"],"gpt_icon":0},{"id":"2590398455","title":"创新药概念股盘初强势 歌礼制药-B(01672)涨20.73% 机构指政策鼓励创新药发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2590398455","media":"金吾财讯","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590398455?lang=zh_cn&edition=full","pubTime":"2025-12-09 09:38","pubTimestamp":1765244314,"startTime":"0","endTime":"0","summary":"中信证券表示，2025年12月7日，2025创新药高质量发展大会在广州举行，国家医保局现场发布了2025年《国家基本医疗保险、生育保险和工伤保险药品目录》及《商业健康保险创新药品目录》。该机构认为，国家医保谈判成功率创历史新高，商保目录有望成为重要增量，政策鼓励创新药发展。看好相关创新药及制药企业。","market":"nz","thumbnail":"https://static.szfiu.com/news/20241108/MmRhZGRhNjQ0NTZmM2ZiNTY3MTMzODA5NjE3MTg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MmRhZGRhNjQ0NTZmM2ZiNTY3MTMzODA5NjE3MTg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1971163","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1593","02157","BK1141","02096","SG9999004220.SGD","01672","BK1161","SG9999015986.USD","01477","BK1583","IE00BVYPNP33.GBP","BK1191","IE00BVYPNQ40.USD","00867","LU2488822045.USD","01952","SG9999014674.SGD","BK1515","IE00BYV24P56.USD","159992","BK1574","SG9999015945.SGD","02268","06978","IE00BMCWC346.EUR","SG9999015978.USD","IE00BGHQDM52.EUR","SG9999015952.SGD"],"gpt_icon":0},{"id":"2590367683","title":"石药创新制药拟将阿卡波糖项目节余募资3621.73万元永久补流","url":"https://stock-news.laohu8.com/highlight/detail?id=2590367683","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590367683?lang=zh_cn&edition=full","pubTime":"2025-12-09 08:33","pubTimestamp":1765240382,"startTime":"0","endTime":"0","summary":"中访网数据 石药创新制药股份有限公司于2025年12月5日召开董事会，审议通过了关于部分募集资金投资项目结项并将节余募集资金永久补充流动资金的议案。公司拟将已实施完毕的“阿卡波糖绿色工厂升级技术改造项目”结项，并将该项目节余的募集资金及利息合计3,621.73万元永久补充流动资金，用于与主营业务相关的经营活动。资金划转后，公司将注销相关募集资金专户，相应的监管协议随之终止。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251209/31852177.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["LU1226288253.USD","BK1521","LU1328277881.USD","SG9999004220.SGD","LU0067412154.USD","LU1813983027.USD","LU2039709279.SGD","01477","LU0326950275.SGD","IE00B5MMRT66.SGD","LU1152091168.USD","IE00B543WZ88.USD","LU1226287529.USD","LU1993786604.SGD","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","IE00BZ08YS42.EUR","BK1191","LU0880133367.SGD","LU1226287875.USD","LU1807302812.USD","IE0008369823.USD","IE00B031HY20.USD","LU0314109678.HKD","HK0000165453.HKD","LU1960683339.HKD","BK1574","LU1152091754.HKD","IE0008368742.USD","LU1008478684.HKD","LU0501845795.SGD","LU1226288170.HKD","LU0315179316.USD","LU1226287792.SGD","LU0072913022.USD","LU0140636845.USD","BK1515","01093","LU1951186391.HKD"],"gpt_icon":0},{"id":"2589443356","title":"Mirum制药拟以最高8.2亿美元收购蓝鸟治疗公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2589443356","media":"环球市场播报","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589443356?lang=zh_cn&edition=full","pubTime":"2025-12-08 22:06","pubTimestamp":1765202760,"startTime":"0","endTime":"0","summary":"Mirum制药于周一宣布，将以最高 8.2 亿美元的价格收购蓝鸟治疗公司，此举将为其产品组合增添一款用于治疗严重肝病的后期实验性药物。　　根据协议条款，Mirum制药将先期支付 2.5 亿美元现金和 3.7 亿美元股票，同时还可能支付最高 2 亿美元的基于销售额的里程碑款项。据Mirum制药披露，近半数确诊患者会在 10 年内死于肝脏相关并发症。　　此项收购交易预计将于 2026 年第一季度完成。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2025-12-08/doc-inhacacc1640273.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","01477","BK1191"],"gpt_icon":0},{"id":"2589332575","title":"贵州三力：证券简称12日起变更为“三力制药”","url":"https://stock-news.laohu8.com/highlight/detail?id=2589332575","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589332575?lang=zh_cn&edition=full","pubTime":"2025-12-08 18:56","pubTimestamp":1765191360,"startTime":"0","endTime":"0","summary":"每经AI快讯，12月8日，贵州三力公告，公司证券简称将于12月12日起由“贵州三力”变更为“三力制药”，公司证券代码“603439”保持不变。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2025-12-08/doc-inhaavvc2311126.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-12-08/doc-inhaavvc2311126.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["603439","BK1191","BK1574","BK0239","161027","01477"],"gpt_icon":0},{"id":"2589533373","title":"兆科眼科-B(06622)拟与东生华制药于台湾地区共同推进BRIMOCHOL™PF的临床导论及未来商业化","url":"https://stock-news.laohu8.com/highlight/detail?id=2589533373","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589533373?lang=zh_cn&edition=full","pubTime":"2025-12-08 16:48","pubTimestamp":1765183700,"startTime":"0","endTime":"0","summary":"智通财经APP讯，兆科眼科-B 公布，公司与以台湾为基地的东生华制药股份有限公司订立策略性伙伴关系，于台湾地区共同推进BRIMOCHOL PF的临床导论及未来商业化。东生华制药精于慢性病及精准医疗，提供安全而易于获取的照护解决方案。根据协议条款，兆科授予东生华制药以独家分销商身份于台湾地区注册、进口、推广、分销、营销及销售BRIMOCHOL PF的权利。于2025年6月，兆科的伙伴兼BRIMOCHOL PF的开发商Tenpoint Therapeutics, Ltd.宣布，美国FDA已受理该药品的新药上市申请。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378791.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01477","BK1583","06622","BK1191","BK1587","BK1574"],"gpt_icon":0},{"id":"2590139696","title":"每日卖空追踪 | 欧康维视生物-B 12月08日卖空量成交2.6万股，卖空比例为4.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590139696","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590139696?lang=zh_cn&edition=full","pubTime":"2025-12-08 16:30","pubTimestamp":1765182620,"startTime":"0","endTime":"0","summary":"欧康维视生物-B北京时间12月08日，涨0.24%，卖空量成交2.6万股，较上一交易日减少73.06%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208163308979613e6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208163308979613e6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01477","BK1191","BK1574"],"gpt_icon":0},{"id":"2590739694","title":"欧康维视生物-B12月08日主力净流入14.4万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2590739694","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590739694?lang=zh_cn&edition=full","pubTime":"2025-12-08 16:15","pubTimestamp":1765181740,"startTime":"0","endTime":"0","summary":"12月08日, 欧康维视生物-B股价涨0.24%，报收8.32元，成交金额455.4万元，换手率0.07%，振幅3.13%，量比0.75。欧康维视生物-B今日主力资金净流入14.4万元，上一交易日主力净流出0万元。该股近5个交易日上涨3.70%，主力资金累计净流出224.4万元；近20日主力资金累计净流出652.0万元，其中净流出天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208161848a72aa569&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208161848a72aa569&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1574","01477"],"gpt_icon":0},{"id":"2589382248","title":"永顺泰：麦芽在食品制药领域需求量相对较小","url":"https://stock-news.laohu8.com/highlight/detail?id=2589382248","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589382248?lang=zh_cn&edition=full","pubTime":"2025-12-08 15:06","pubTimestamp":1765177582,"startTime":"0","endTime":"0","summary":"证券之星消息，永顺泰(001338)12月08日在投资者关系平台上答复投资者关心的问题。投资者提问：除啤酒酿造外，永顺泰麦芽在食品、制药等大消费新兴领域的需求规模及市场开拓进展如何？永顺泰回复：麦芽在食品、制药等大消费新兴领域的应用目前需求量相对较小。麦芽绝大部分用于啤酒酿造，也可用于威士忌酿造、食品、制药等领域。公司目前主要的销售对象是啤酒酿造企业。公司未来将根据市场需求变化，持续优化产品结构，探索新的应用场景。谢谢关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120800012352.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0215","BK1191","001338","01477","BK1574"],"gpt_icon":0},{"id":"2589381237","title":"歌礼制药-B(01672.HK)涨超4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2589381237","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589381237?lang=zh_cn&edition=full","pubTime":"2025-12-08 13:56","pubTimestamp":1765173414,"startTime":"0","endTime":"0","summary":"每经AI快讯，歌礼制药-B(01672.HK)涨超4%，截至发稿涨4.25%，报14.23港元，成交额2682.71万港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512083585200140.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512083585200140.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["01672","BK1161","BK1191","BK1574","01477","BK1515"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ocumension.com","stockEarnings":[{"period":"1week","weight":0.0469},{"period":"1month","weight":-0.0506},{"period":"3month","weight":-0.136},{"period":"6month","weight":-0.1614},{"period":"1year","weight":0.6487},{"period":"ytd","weight":0.8356}],"compareEarnings":[{"period":"1week","weight":-0.0085},{"period":"1month","weight":-0.0416},{"period":"3month","weight":-0.0209},{"period":"6month","weight":0.069},{"period":"1year","weight":0.2575},{"period":"ytd","weight":0.2732}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"欧康维视生物是一家控股公司，主要从事眼科治疗药物的研发和商业化。该公司主要产品包括OT-401 (YUTIQ)、OT-1001 (ZERVIATE)、OT-502 (DEXYCU)、OT-301 (NCX 470)、OT-101和OT-202等。该公司业务主要在国内市场开展。","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.116968},{"month":2,"riseRate":0.4,"avgChangeRate":-0.049128},{"month":3,"riseRate":0.6,"avgChangeRate":0.058111},{"month":4,"riseRate":0.4,"avgChangeRate":0.017956},{"month":5,"riseRate":0.6,"avgChangeRate":0.137077},{"month":6,"riseRate":0.8,"avgChangeRate":0.129408},{"month":7,"riseRate":0.4,"avgChangeRate":-0.027707},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.064893},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.082685},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.121217},{"month":11,"riseRate":0.333333,"avgChangeRate":0.004503},{"month":12,"riseRate":0.666667,"avgChangeRate":0.075568}],"exchange":"SEHK","name":"欧康维视生物-B","nameEN":"OCUMENSION-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"欧康维视生物-B(01477)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供欧康维视生物-B(01477)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"欧康维视生物-B,01477,欧康维视生物-B股票,欧康维视生物-B股票老虎,欧康维视生物-B股票老虎国际,欧康维视生物-B行情,欧康维视生物-B股票行情,欧康维视生物-B股价,欧康维视生物-B股市,欧康维视生物-B股票价格,欧康维视生物-B股票交易,欧康维视生物-B股票购买,欧康维视生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"欧康维视生物-B(01477)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供欧康维视生物-B(01477)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}